Dow Up0.51% Nasdaq Up0.24%

Peregrine Pharmaceuticals, Inc. (PPHM)

1.43 Up 0.02(1.42%) Nov 21, 4:00PM EST
|After Hours : 1.43 Up 0.00 (0.01%) Nov 21, 4:45PM EST
ProfileGet Profile for:
Peregrine Pharmaceuticals, Inc.
14282 Franklin Avenue
Tustin, CA 92780
United States - Map
Phone: 714-508-6000

Index Membership:N/A
Full Time Employees:180

Business Summary 

Peregrine Pharmaceuticals, Inc., a biopharmaceutical company, is engaged in the research and development of novel monoclonal antibodies for the treatment and diagnosis of cancer in the United States. Its lead immunotherapy candidate, bavituximab, is in Phase III development for the treatment of second-line non-small cell lung cancer along with various investigator-sponsored trials evaluating other treatment combinations and additional oncology indications. The company is also evaluating its lead molecular imaging agent, 124I-PGN650, in an exploratory clinical trial for the imaging of various solid tumor types. In addition, it provides contract manufacturing services ranging from cell line development to commercial current good manufacturing practice biomanufacturing to third-party clients. The company has various license agreements with the University of Texas Southwestern Medical Center at Dallas; Genentech, Inc.; Avanir Pharmaceuticals, Inc.; Lonza Biologics; Affitech A/S; and Merck KGaA. Peregrine Pharmaceuticals, Inc. was founded in 1981 and is headquartered in Tustin, California.

Key Statistics

Company Websites 
Home Page
Search Yahoo! for:
More on Peregrine Pharmaceuticals, Inc.

Corporate Governance 
Peregrine Pharmaceuticals, Inc.’s ISS Governance QuickScore as of Nov 1, 2014 is 10. The pillar scores are Audit: 1; Board: 9; Shareholder Rights: 9; Compensation: 10.
Brought to you by Institutional Shareholder Services (ISS)

Key Executives 
Mr. Steven W. King , 50
Chief Exec. Officer, Pres, Director, Chief Exec. Officer of Avid Bioservices Inc and Pres of Avid Bioservices Inc
Mr. Paul J. Lytle CPA, 46
Chief Financial Officer and Principal Accounting Officer
Mr. Mark R. Ziebell J.D., 50
VP, Gen. Counsel and Corp. Sec.
Dr. Shelley P. M. Fussey Ph.D., 48
VP of Intellectual Property
Mr. Joseph S. Shan M.P.H., 41
VP of Clinical & Regulatory Affairs
Amounts are as of Dec 31, 2014 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
Currency in USD.
View Insiders